UroGen: Expect Rough Patch Before Strong Recovery In 2026

UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
Becker's ASC

Redefining surgical access: How ASCs transform the healthcare ecosystem

Ambulatory surgery centers (ASCs) are increasingly important to health systems’ long-term growth strategies. ASC partnerships or purchases can increase a health system’s revenue and capacity and ...
Nasdaq

First Trust Senior Floating Rate Income Fund II Common Shares of Beneficial Interest (FCT)

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...
Everyday Health

Why More Couples Are Divorcing at Older Ages (and After More Years of Marriage) Than Before — and What You Can Do to Avoid It

Baby boomers have gotten credit for all kinds of societal trends, from the counterculture to consumerism. Now they’re behind what’s known as “gray divorce” — couples calling it quits in middle age or ...